Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Fig. 3

Memory phenotypes of CD7 CAR-T-cell subsets and expression of exhaustion markers in vitro. A, B Distribution of naïve-like T (TN) cells (CD45RO−CCR7+), central memory-like T (TCM) cells (CD45RO+CCR7+), effector memory-like T (TEM) cells (CD45RO+CCR7−), and effector-like T (TEff) (CD45RO−CCR7−) of CD7 CAR T or NTR in CD3+CD4+ or CD3+CD8+ subsets measured at Day 12 post transduction (n = 3). C–F Expression of exhaustion markers (PD-1, TIM-3, LAG-3) in CD7 CAR-T cells versus nontransduced T (NTR) cells at Day 12 post transduction (n = 3). ns, not significant; *P < 0.01; **P < 0.01

Back to article page